| IPAD-DB ID | C01260 | 
| Name | Ginsenoside Re | 
| Category | Natural compounds | 
| 2D Structure | 
                             | 
                    
| 3D Structure | |
| Molecular Formula | C 4 8 H 8 2 O 1 8 | 
| Molecular Weight | 947.2 g/mol | 
| IUPAC Name | (2S, 3R, 4R, 5R, 6S)-2-[(2R, 3R, 4S, 5S, 6R)-2-[[(3S, 5R, 6S, 8R, 9R, 10R, 12R, 13R, 14R, 17S)-3, 12-dihydroxy-4, 4, 8, 10, 14-pentamethyl-17-[(2S)-6-methyl-2-[(2S, 3R, 4S, 5S, 6R)-3, 4, 5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2, 3, 5, 6, 7, 9, 11, 12, 13, 15, 16, 17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-4, 5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-methyloxane-3, 4, 5-triol | 
| InChI | InChI=1S/C48H82O18/c1-21(2)11-10-14-48(9, 66-42-38(60)35(57)32(54)26(19-49)63-42)23-12-16-46(7)30(23)24(51)17-28-45(6)15-13-29(52)44(4, 5)40(45)25(18-47(28, 46)8)62-43-39(36(58)33(55)27(20-50)64-43)65-41-37(59)34(56)31(53)22(3)61-41/h11, 22-43, 49-60H, 10, 12-20H2, 1-9H3/t22-, 23-, 24+, 25-, 26+, 27+, 28+, 29-, 30-, 31-, 32+, 33+, 34+, 35-, 36-, 37+, 38+, 39+, 40-, 41-, 42-, 43+, 45+, 46+, 47+, 48-/m0/s1 | 
| InChIKey | PWAOOJDMFUQOKB-WCZZMFLVSA-N | 
| Canonical SMILES | CC1C(C(C(C(O1)OC2C(C(C(OC2OC3CC4(C(CC(C5C4(CCC5C(C)(CCC=C(C)C)OC6C(C(C(C(O6)CO)O)O)O)C)O)C7(C3C(C(CC7)O)(C)C)C)C)CO)O)O)O)O)O | 
| PubChem CID | 441921 | 
| DrugBank Accession Number | DB14815 | 
| CAS Registry Number | 52286-59-6 | 
| Molecular Weight(Computed by SwissADME) | 947.15 | 
| Hac(Computed by SwissADME) | 66 | 
| Volume(Computed by ADMETlab 2.0) | 934.456 | 
| Density(Computed by ADMETlab 2.0) | 1.013 | 
| nRing(Computed by ADMETlab 2.0) | 7 | 
| MaxRing(Computed by ADMETlab 2.0) | 17 | 
| nHet(Computed by ADMETlab 2.0) | 18 | 
| fChar(Computed by ADMETlab 2.0) | 0 | 
| nRig(Computed by ADMETlab 2.0) | 39 | 
| Flexibility(Computed by ADMETlab 2.0) | 0.308 | 
| Stero Centers(Computed by ADMETlab 2.0) | 26 | 
| LogS(Computed by ADMETlab 2.0) | -2.874 | 
| LogD(Computed by ADMETlab 2.0) | 2.088 | 
| logP(Computed by ADMETlab 2.0) | 1.448 | 
| TPSA(Computed by SwissADME) | 298.14 | 
| Hbond Acceptor(Computed by SwissADME) | 18 | 
| Hbond Donor(Computed by SwissADME) | 12 | 
| Rotatable Bonds(Computed by SwissADME) | 
| GI Absorption(Computed by SwissADME) | Low | 
| BBB(blood-brain barrier) Permeant(Computed by SwissADME) | No | 
| P-gp Substrate(Computed by SwissADME) | Yes | 
| CYP1A2 Inhibitor(Computed by SwissADME) | No | 
| CYP2C19 Inhibitor(Computed by SwissADME) | No | 
| CYP2C9 Inhibitor(Computed by SwissADME) | No | 
| CYP2D6 Inhibitor(Computed by SwissADME) | No | 
| CYP3A4 Inhibitor(Computed by SwissADME) | No | 
| log Kp(Skin Permeation)(Computed by SwissADME) | -10.96 | 
| Lipinski(Computed by SwissADME) | 3 | 
| Ghose(Computed by SwissADME) | 3 | 
| Veber(Computed by SwissADME) | 2 | 
| Egan(Computed by SwissADME) | 1 | 
| Muegge(Computed by SwissADME) | 4 | 
| Bioavailability Score(Computed by SwissADME) | 0.17 |